Neurelis: Funding, Investors & Team (Sep 2026)
Neurelis is a specialty pharmaceutical company, licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market. It provides a differentiated approach to target unmet medical needs. Their application of novel technologies is designed to enhance the therapeutic benefit and patient care. The company was incorporated in 2007 and is based in Encinitas, California.
Neurelis has raised $114M across 1 funding round on record, the most recent a Series D of $114M announced in Mar 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Neurelis Company Profile and Key Stats
Latest funding round on record: Mar 2021.
Neurelis Funding Rounds
Neurelis Founders and Leadership Team
Contact details for the Neurelis team: 1 of 1 has an email address on file.
Start 14-day free trial →Neurelis Funding Compared to Other Biotechnology Startups
Neurelis' latest round of $114M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Neurelis in Biotechnology and Encinitas
Companies Similar to Neurelis
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Neurelis Funding FAQs
What does Neurelis do?
Neurelis is a specialty pharmaceutical company, licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market. It provides a differentiated approach to target unmet medical needs. Their application of novel technologies is designed to enhance the therapeutic benefit and patient care. The company was incorporated in 2007 and is based in Encinitas, California.
How much funding has Neurelis raised?
Neurelis has raised $114M across 1 round on record. The most recent is a Series D of $114M announced in Mar 2021.
When did Neurelis last raise funding?
Neurelis' most recent funding round on record is a Series D of $114M, announced in Mar 2021.
Who is the CEO of Neurelis?
Craig Chambliss is listed as CEO at Neurelis.
Where is Neurelis headquartered?
Neurelis is based in Encinitas, California, United States.
How many employees does Neurelis have?
Neurelis is in the 101-250 employee band.
How does Neurelis' funding compare to other Biotechnology startups?
Neurelis' latest round of $114M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Neurelis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Neurelis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.